Institutional shares held 66.8 Million
41.1K calls
112K puts
Total value of holdings $559M
$344K calls
$935K puts
Market Cap $371M
45,612,200 Shares Out.
Institutional ownership 146.48%
# of Institutions 152


Latest Institutional Activity in CGEM

Top Purchases

Q1 2025
Palumbo Wealth Management LLC Shares Held: 16.3K ($132K)
Q1 2025
Exchange Traded Concepts, LLC Shares Held: 14.1K ($115K)
Q1 2025
Rhumbline Advisers Shares Held: 71.3K ($581K)
Q1 2025
Farther Finance Advisors, LLC Shares Held: 1.01K ($8.25K)
Q1 2025
Rothschild Investment LLC Shares Held: 245 ($1.99K)

Top Sells

Q1 2025
Assenagon Asset Management S.A. Shares Held: 10.1K ($81.9K)
Q1 2025
Sg Americas Securities, LLC Shares Held: 16.6K ($135K)
Q1 2025
Gamma Investing LLC Shares Held: 924 ($7.52K)
Q4 2024
Marshall Wace, LLP Shares Held: 652K ($5.3M)
Q4 2024
Adage Capital Partners Gp, L.L.C. Shares Held: 1.03M ($8.39M)

About CGEM

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at CGEM

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
620K Shares
From 9 Insiders
Grant, award, or other acquisition 546K shares
Exercise of conversion of derivative security 74.1K shares
Sell / Disposition
141K Shares
From 4 Insiders
Open market or private sale 141K shares

Track Institutional and Insider Activities on CGEM

Follow Cullinan Oncology, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CGEM shares.

Notify only if

Insider Trading

Get notified when an Cullinan Oncology, Inc. insider buys or sells CGEM shares.

Notify only if

News

Receive news related to Cullinan Oncology, Inc.

Track Activities on CGEM